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Despite the important progress obtained in the treatment of some pets’ malignancies, new treatments need to be developed. Being
critical in cancer control and progression, the immune system’s appropriate modulation may provide effective therapeutic options.
In this review we summarize the outcomes of published immunogene therapy veterinary clinical trials reported by many research
centers. A variety of tumors such as canine melanoma, soft tissue sarcomas, osteosarcoma and lymphoma, feline fibrosarcoma, and
equine melanoma were subjected to different treatment approaches. Both viral and mainly nonviral vectors were used to deliver
gene products as cytokines, xenogeneic tumor associated antigens, specific ligands, and proapoptotic regulatory factors. In some
cases autologous, allogenic, or xenogeneic transgenic cytokine producing cells were assayed. In general terms, minor or no adverse
collateral effects appeared during this kind of therapies and treated patients usually displayed a better course of the disease (longer
survival, delayed or suppressed recurrence or metastatic spread, and improvement of the quality of life). This suggests the utility
of these methodologies as standard adjuvant treatments. The encouraging outcomes obtained in companion animals support their
ready application in veterinary clinical oncology and serve as preclinical proof of concept and safety assay for future human gene
therapy trials.
1. Introduction
Gene therapy provides novel strategies to treat many cancers
that lack suitable approved treatments. Cancer gene therapy
clinical trials started significantly earlier in human beings [1]
than in companion animals [2]. Both trials involved immuno-
gene therapy that is based on the expression of transgenes
engaged in immune responses [3].
Although the convenience of comparative oncology for
translational approaches was strongly encouraged for many
years [4, 5], until now (June 2014) there was a significantly
higher number of human (1331) than companion animal (48)
cancer gene therapy trials (http://www.wiley.com/legacy/
wileychi/genmed/clinical/).
Manipulating the immune system in order to induce clin-
ically relevant responses against cancer is a longstanding goal,
and gene transfer offers a suitable approach to reach it.
As it happens in human clinical trials, cancer immuno-
gene therapy is largely leading themajor attention in compan-
ion animal trials. Most of the veterinary patients were canine
[6], while some reports were derived from feline and equine
patients [7]. Different kinds of tumors were targeted, being
highly aggressive spontaneous canine melanoma the pre-
ferred model. Both viral [8, 9] and nonviral [10] vectors as
well as therapeutic gene producing transgenic cells were used
to deliver gene products such as cytokines, suicide genes,
tumor antigens, and proapoptotic genes [6, 7, 11]. In the last
decade, the advances in physical and chemical methods to
deliver plasmid DNA into tumor tissue and normal tissue are
showing promise in narrowing the gap between viral and
nonviral gene delivery efficiency [12].
We focused this review only on reports of clinical data
collected from client-owned patients with spontaneously
arising tumors. Canine, feline, and equine trials were sepa-
rately displayed in Tables 1, 2, and 3.
2. Canine Melanoma
Spontaneous canine melanoma is a highly aggressive tumor
of the oral cavity, digit/footpad, and mucocutaneous junc-
tions; it appears clinically similar to aggressive human
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Table 2: Feline cancer immunogene therapy trials.
# Genes Tumor Vector Mode Results Authors/year/referenceCytokines
1 hIL-2 FSA
Irradiated xenogeneic
hIL-2 producing cells made
by plasmid transfection
Ex vivo/p.t./
+SX + RX
(𝑛 = 16) no relapse at 480 d: 5.
Control/11. Treated: 11. Median
survival: control: 240 d/treated:
>480 d
Quintin-Colonna
et al., 1996 [2]
2 hIL-2/fIL-2 FSA Poxviruses In vivo − i.t./+SX + RX
(𝑛 = 18) no relapse at 365 d: control:
7/treated: 13 fIL-2:/11 hIL-2
Jourdier et al., 2003
[50]
3 fIL-12 FSA Adenovirus In vivo − i.t./+RX + HT
(𝑛 = 13) feasible and manageable
toxicity. Maximally tolerated safe
dose: 1010 pfu
Siddiqui et al.,
2007 [51]
4
fIL-2 +
fIFN-𝛾 +
fGM-CSF
FSA
Iron oxide PEI-complexed
plasmid enhanced by
magnetofection
In vivo − i.t./
+SX
(𝑛 = 21) dose escalation and safety.
Maximal dose of plasmids (450 𝜇g
each) was well tolerated. Maximal
effects expected at 150𝜇g
Jahnke et al., 2007
[52]
5 fGM-CSF FSA
Iron oxide PEI-complexed
plasmid enhanced by
magnetofection
In vivo − i.t./
+SX
(𝑛 = 20) (𝑛 = 25) dose escalation
and safety. Maximal dose of plasmid
(1250𝜇g) was well tolerated. 10
recurrence free after 360 d.
Hu¨ttinger et al.,
2008 [53]
hIL-2, human interleukin-2; fIL-12, feline interleukin-12; fIL-2, feline interleukin-2; fIFN-𝛾, feline interferon-𝛾; fGM-CSF, feline granulocytemacrophage colony
stimulating factor; FSA, fibrosarcoma; i.t., intratumoral; p.t., peritumoral; HT, hyperthermia; RX, radiotherapy; SX, surgical excision; d, days.
Table 3: Equine cancer immunogene therapy trials.
# Genes Tumor Vector Mode Results Authors/year/referenceCytokines Equine
1 hIL-12 MEL Naked plasmid In vivo − i.t./NAT
(𝑛 = 7) PR: 59 % reduction of injected
tumors burden
Heinzerling et al.,
2001 [56]
2 eIL-12 MEL Naked plasmid In vivo − i.t./NAT
(𝑛 = 7) feasibility assessed,
pharmacokinetics, and
pharmacodynamics of biological activity.
Mu¨ller et al., 2011
[58]
3 hIL-12/hIL-18 MEL Naked plasmid
In vivo − i.t./
NAT
Controlled assay. (𝑛 = 8) hIL-12, 6 PR;
(𝑛 = 9) hIL-18, 5 PR. Both are very well
tolerated.
Mu¨ller et al., 2011
[57]
4
hIL-2 +
hGM-CSF
HSV-tk
MEL
Plasmid/cationic lipid
for HSV-tk + GCV.
Irradiated xenogeneic
hIL-2 and hGM-CSF
producing cells made
by plasmid lipofection
In vivo (SG)
− i.t. Ex vivo
(CPXC) +
(TV) −
s.c./+SX
(𝑛 = 1) case report. Reduction of injected
tumors burden. Prevention of
postsurgical local relapse. Survival
>600 d.
Finocchiaro et al.,
2009 [55]
hIL-12, human interleukin-12; eIL-12, equine interleukin-12; hIL-18, human interleukin-18;HSV-tk, herpes simplex thymidine kinase; hIL-2, human interleukin-
2; hGM-CSF, human granulocyte macrophage colony stimulating factor; MEL, melanoma; CPXC, cytokine producing xenogeneic cells; GCV, ganciclovir; SG,
suicide gene; TV, tumor vaccine; i.t., intratumoral; s.c., subcutaneous; NAT, no additional treatment during or following gene therapy; SX, surgical excision; d,
days.
melanoma. Both diseases are chemo- and radioresistant, do
not respond well to treatment with conventional biological
response modifiers, and share similar metastatic phenotypes
and site selectivity [4, 5]. At the time of diagnosis, the disease
is often metastatic and has an extremely poor prognosis
because of rapid invasion of surrounding normal tissue and
high likelihood of regional and distant metastasis early in the
course of the disease. The high metastatic rate observed with
this disease and the inefficacy of current therapies warranted
the investigation into novel therapies.
The pioneering work published about 18 years ago [2]
described an ex vivo genetically engineered xenogeneic cell
gene therapy approach where the effects of repeated peritu-
moral local injections of human interleukin-2 (hIL-2) secret-
ing Vero cells after surgical removal of the tumor followed by
60Co-radiotherapy were evaluated. This combined treatment
resulted in a considerably higher median survival of 270 days
compared to 75 days of the surgery plus radiation controls
(𝑛 = 16, each group). The treatment resulted was safe.
A couple of years later, an individually targeted autol-
ogous ex vivo approach for spontaneous canine melanoma
involving human granulocyte and macrophage colony stim-
ulating factor (hGM-CSF) gene transfer was reported [13]. In
this case, after tumor removal, a suspension of tumor cells
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was subjected to a gene gun shot with gold particles coated
with a plasmid carrying the human GM-CSF gene. After
sublethal 137Cs irradiation, transgenic cells were delivered as
intradermal injections in the flank of the patients. As part of
phase I clinical trial, the treatment of 10 canine melanoma
bearing patients resulted in 3 objective responses and 1 stable
disease, while 3 cases of fibrosarcoma yielded 2 objective
responses. No animal exhibited any signs of local or systemic
toxicity. Even though it is statistically nonsignificant because
the low number of cases, survival time of melanoma respon-
ders (>300 days) largely exceeded the expected values for
surgery treated patients (90–165 days).
By using intratumoral injections of bacterial superanti-
gen gene (staphylococcal enterotoxin B, SEB) as immune-
adjuvant plus the immunostimulatory gene canine GM-CSF,
the objective responses andmedian survivals for spontaneous
canine melanoma were as follows: stage I, 3/3-427 days; stage
II, 3/5-399 days; stage III, 4/12-168 days; stage IV, 0/2-n.d.
Median survival (168 days) of stage III patients (𝑛 = 12)
resulted significantly higher than historical surgery controls
(105 days) [14]. Intratumoral expression of SEB and canine
GM-CSF genes carrying plasmid did not induce clinically
significant toxicity in treated dogs.
A totally different approach to promote immunologic
“priming” through induction of apoptosis was assayed for
canine melanoma [15]. Direct intratumoral injections of a
plasmid carrying the human Fas ligand (hFasL) gene caused
a quick reduction (7 days) of tumor burden that was seen in
3 of 5 treated dogs. At that time, each dog was provided with
standard care therapy as indicated for each tumor (surgery,
radiation, or palliation), and the final result was 4 objective
responses with survivals ranging from 168 to 574 days. The
treatment did not show any adverse effect.
On the other hand, intramuscular needle free jet injection
of a plasmid containing human tyrosinase gene and its
expression as a melanoma xenoantigen considerably pro-
longed the median survival of canine melanoma bearing
patients up to 389 days as compared with historical controls
subjected to standard treatments (60–150 days) [16]. In addi-
tion, at least two long-term survivors displayed detectable
levels of humoral anti-human tyrosinase antibodies [17].
Fifty-eight patients were enrolled in a larger trial to evaluate
the safety and efficacy of this DNA vaccine as adjunctive
treatment for oral malignant canine melanoma in which
locoregional disease control was achieved [18]. While both
safety and efficacy were confirmed, the median survival
due to melanoma was significantly higher (>750 days) as
compared to historical controls (324 days) and reported only
14/58 deaths were due to melanoma compared to 34/53 in
reported historical controls [19]. In a further trial, hTyr and
other xenogeneicDNAs coding formurine tyrosinase (mTyr),
murine gp75, and humanGM-CSFwere assayed at increasing
doses. Combinations of mTyr and hGM-CSF were also eval-
uated [20]. Thirty-three stage II-III dogs with locoregionally
controlled canine melanoma across the xenogeneic vaccine
studies displayed a median survival time of 569 days, largely
exceeding the value expected for standard treatments. Min-
imal to mild pain was noted at vaccination sites. All these
results served to support the approval of the first therapeutic
cancer vaccine available in the veterinary pharmaceutical
market. As a continuation of these studies, a new one deter-
mined the safety and effectiveness of the murine tyrosinase
xenogeneic vaccine for canine digit melanoma when used
in conjunction with local and regional disease control [21].
This retrospective study suggests a prolongation of survival
for dogs with melanoma of the digit treated with xenogeneic
DNA melanoma vaccine (a median survival time: 476 days)
compared with historical controls treated with surgery alone
(a median survival time: 365 days). A survival advantage was
noted for those dogs that were vaccinated near the time of
diagnosis over those dogs that had a significant delay between
diagnosis and vaccination.
An independent retrospective study of 22 hTyr vaccinated
versus 23 nonvaccinated melanoma-bearing dogs did not
show significant differences in progression-free survival,
disease-free interval, or median survival time [22]. This new
outcome suggests the need of new controlled trials with a
larger amount of patients.
Autologous dendritic cells pulsed with adenoviral vector
encoding human gp100 were successfully produced and
applied as radiotherapy adjuvant to treat canine melanoma
[23]. The 3 treated patients exceeded the expected median
survival (210–1440 days), even though one died sooner
because of progressive disease. No adverse effects were
observed in any of the treated dogs with either the priming
or the subsequent vaccine booster doses.
In a different approach involving vaccination with allo-
geneic melanoma cells expressing xenogeneic human gp100,
melanoma bearing dogs experiencing tumor control survived
significantly longer than dogs having no response (median
survivals: 337 days versus 95 days) [24]. Adverse reactions
were limited to mild induration and erythema at the site of
vaccination.
A feasibility study was performed for adenovector CD40
ligand (AdCD40L) immunogene treatment [25]. One case of
advanced stage III oral melanoma, treated by intratumoral
vaccination followed by cytoreductive surgery, did not relapse
and survived for 401 days. A second case of conjunctival
malignant melanoma, treated only with intralesional injec-
tions, showed a continuous remission formore than 150 days.
Only reversible minor side effects were reported. Following
this research, a pilot study to treat canine melanoma (14
oral, 4 cutaneous, and 1 conjunctival) with local AdCD40L
was reported [26]. One to 6 intratumoral injections of
AdCD40L were given every 7 days, followed by cytoreductive
surgery in 9 cases and only immunotherapy in 10 cases.
Posttreatment Immune stimulation was evidenced by tumor
tissue infiltration with T and B lymphocyte. The best overall
response included 5 complete responses, 8 partial responses,
and 4 stable and 2 progressive diseases. Median survival was
160 days (range, 20–1141 days), with 3 dogs still alive at sub-
mission. This work demonstrated that local AdCD40L ther-
apy was safe and could have beneficial effects on dogs.
The immunogenicity, safety, and therapeutic efficacy of a
human chondroitin sulfate proteoglycan-4 (hCSPG4) DNA-
based vaccine were evaluated [27]. Dogs with stage II-III
surgically resectedCSPG4-positive oralmalignantmelanoma
were subjected to monthly intramuscular plasmid adminis-
tration, which was followed immediately by electroporation
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(electrovaccination) from 6 to 20months. Overall (653 versus
220 days) and disease-free (477 versus 180 days) survival
times were significantly longer in 14 vaccinated dogs as com-
pared with 13 nonvaccinated controls. No clinically relevant
local or systemic side effects were found. This suggested
that xenogeneic electrovaccination against CSPG4 is able to
overcome host unresponsiveness to the “self ” antigen and
seems to be effective in treating canine malignant melanoma.
By adding local herpes simplex virus thymidine kinase
(HSV-tk) suicide gene bearing plasmid plus ganciclovir, in an
approach that included intratumoral injections of xenogeneic
hamster cells secreting hIL-2 and hGM-CSF (𝑛 = 45),
melanoma bearing dogs presenting local objective responses
survived significantly longer than dogs lacking local objective
responses (220 days versus 151 days), being both responses
considerably higher than those of surgery controls (82 days)
[28].
As a continuation of these encouraging data, a surgery
adjuvant treatment against the minimal residual disease
whose rationale appeared to be considerably superior to
the previous intratumoral treatment was assayed [29, 30].
This new treatment consisted of complete or cytoreductive
surgery followed by a combination of suicide gene therapy
with a subcutaneous vaccine. This vaccine was a mixture of
formolized tumor cells and irradiated xenogeneic cells pro-
ducing hIL-2 and hGM-CSF. The postsurgical margin of the
cavity was infiltrated with lipid-complexed HSV-tk suicide
gene coadministrated with ganciclovir. Toxicity was absent or
minimal in all patients. With respect to surgery-treated con-
trols (ST), the complete surgery (CS) arm of this combined
treatment (CT) significantly increased the fraction of local
disease-free patients from 13 to 81% and distant metastases
free from 32 to 84%. Even though it is less effective than
the CS arm, the partial surgery (PS) arm of this CT was
significantly better controlling the disease than only surgery
(14% while PS-ST: 0% and CS-ST: 5%). In addition, CT pro-
duced a significant sevenfold (CS) and threefold (PS) increase
in overall survival. The CS-CT arm significantly improved
both CS-ST metastasis-free and melanoma overall survival
from 99 days (respective ranges: 11–563 and 10–568) to >2848
days (81–2848 and 35–2848). Thus, more of 50% of CT
patients died of melanoma unrelated causes, transforming a
lethal disease into a chronic one. After an extensive follow-up
(9 years) with a high number of treated patients (𝑛 = 283),
this study suggested that the most optimal clinical setting
is this surgery adjuvant treatment against minimal residual
disease.
To overcome the limitations imposed by the costly pro-
duction and delivery of cytokine producing transgenic xeno-
geneic cells as well as the appearance of canine melanoma
resistant to suicide gene therapy, we designed a new trial
where these cells were replaced by lipoplexes carrying the
corresponding cytokines genes in the subcutaneous vaccine
and canine interferon-𝛽 (cIFN-𝛽) strengthened the local
antitumor effects [31]. After 6 years of follow-up, 301 canine
patients were subjected to the combined treatment as surgery
adjuvant and 162 remained as surgery controls. While main-
taining a similar efficacy and safety profile with respect to
the previous trial [30], patients subjected to partial surgery
followed by the combined treatment displayed significantly
longer overall survivals.
In summary, the strategy combining local antitumor
gene therapy together with a systemic vaccine enhanced by
cytokines not only delayed or prevented recurrence and dis-
tant metastasis, but also substantially extended disease-free
and overall survival, with a consequent improvement in the
quality of life.
3. Canine Soft Tissue Sarcoma
Soft tissue sarcomas involve a group of tumors with differing
morphological features that share similar biological behav-
iors. These tumors arise from many nonbony connective
tissues and may originate in visceral and nonvisceral sites,
comprising approximately 15% of all skin and subcutaneous
tumors in the dog [32]. Wide surgical excision remains the
cornerstone of treatment for these tumors. Local recurrence
is common following conservative resection, and recurrent
tumors are more difficult to treat.
A superantigen gene was assayed to enhance the action of
immunostimulant cytokine gene, in this case against the inva-
sive spontaneous canine soft tissue sarcoma that is refractory
to most conventional therapies other than surgical excision.
So the effects of intralesional treatment with a plasmid con-
taining bacterial superantigen gene (staphylococcal entero-
toxin A, SEA) plus immunostimulatory canine IL-2 gene
before surgical resection or exploration and biopsy of the
tumor bedwere reported [33]. Adverse effects related to treat-
ment were transient and manageable, and the median sur-
vival of the responders was >540 days without experiencing
local recurrence or metastasis.
A polygene therapy approach was also assayed by our
unit [34]. Eleven soft tissue sarcoma canine patients were
subjected to (i) periodic subcutaneous injection of irradiated
xenogeneic cells secreting hGM-CSF and hIL-2 mixed with
allogeneic or autologous tumor homogenates; and (ii) injec-
tions of cIFN-𝛽 and HSV-tk-carrying lipoplexes and ganci-
clovir, marginally (after surgery), and/or intratumorally (in
the case of partial tumor resection, local relapse, or small
surface tumors). This treatment alone or as surgery adjuvant
was safe and well tolerated. In those patients presenting
local disease (6/11), the suicide gene plus cIFN-𝛽 treatment
induced local antitumor activity evidenced by the objective
response (3 complete, 1 partial) and stable disease (2). In
addition, the treatment prevented or delayed local relapse,
regionalmetastases (lymphnodes developed only in 1/11), and
distant metastases (0/11), suggesting a strong systemic antitu-
mor immunity. Most of the patients displayed long survival
times whilemaintaining a good quality of life: 2 about 4 years,
2 about 3 years, 1 more than 2 years, 4 more than 1 year, and
2 more than 6 months.
4. Canine Osteosarcoma
Osteosarcoma accounts for approximately 85% of primary
bone cancers in the dog [35]. It is a common cancer of large
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to giant breed dogs, and it occurs primarily in the appen-
dicular skeleton. Osteosarcoma in dogs is a common and
highly metastatic tumor that biologically closely resembles
osteosarcoma in humans [4, 5] and does not have additional
treatment options when adjuvant chemotherapy has failed
against its disseminated form [36]. Even with removal of
the primary tumor before spread of the cancer is clinically
detectable, metastases to lung, bone, or other sites eventually
develop in almost all dogs [35].
Metastatic disease often needs a systemic delivery of the
therapeuticmolecule to reachmultiple points simultaneously.
Systemic gene delivery by intravenous injection of cationic
liposome-DNA complexes carrying canine IL-2 gene was
assayed in 22 dogs with chemotherapy-resistant osteosar-
coma lung metastases [36]. The treatment was well tolerated
with 3 dogs displayingmedium-term objective responses and
4 cases of stable disease. A significant increase of the median
survival (82 d) with respect to untreated controls (58 d) was
observed.
As it was the case for soft tissue sarcomas [34], 6 oste-
osarcoma bearing patients were subjected to a treatment
combining (i) the local antiproliferative effects of cIFN-𝛽 and
HSV-tk suicide gene therapywith (ii) the systemic effects trig-
gered by osteosarcoma antigens in an immunostimulatory
environment created by the slow secretion of hGM-CSF and
hIL-2 [37]. Beyond the high safety standard of the proposed
treatment on all the patients, 4 of them survived more than
6 months (among them, two exceeded 1 year). In addition,
the treatment prevented or delayed local relapse, regional
metastases, and distant metastases, suggesting a strong sys-
temic antitumor immunity. The use of this treatment after
surgical removal of the tumor was safe and could delay
or prevent postsurgical recurrence and metastases, with the
consequent quality of life and survival rate improvement. In
addition, when diagnosed at the early stages, a peritumoral
application of cIFN-𝛽 plus suicide genes in combination
with subcutaneous vaccine could be effective in controlling
both local (recurrence) and distant disease (metastases), as
evidenced by one case of long-lasting complete remission
(last update: >453 days) without surgical intervention.
More recently, intratumoral FasL gene was delivered
before surgery in an adenovirus vector (Ad-FasL) as neoad-
juvant to standard of care in 56 canine osteosarcoma patients
[38]. Tumors from treated dogs had greater inflammation,
necrosis, apoptosis, and fibrosis compared to the pretreat-
ment condition or no treated dogs. Survival correlated with
the degree of inflammation or lymphocyte-infiltration scores,
as well as apoptosis scores.
5. Canine Lymphoma
Lymphoma represents the most frequent hematopoietic can-
cer in dogs and often presents in advanced stage (III–V) at
diagnosis and, most commonly, has an aggressive clinical
course requiring prompt treatment. However, although
complete remission may be achieved using multiagent
chemotherapy, themortality rate from this neoplasm remains
high [39].
The use of hGM-CSF secreting autologous tumor cell
vaccine was safe, but it did not result in clinical benefit for
canine B-cell lymphoma patients [40].
In another ex vivo approach, Emm55, a Streptococcus
pyogenes serotyping antigen gene, was transferred to autol-
ogous tumor cells of 7 canine lymphoma patients [41]. Once t
reated, all of them developed an antibody response to mult-
iple autologous tumor antigens and CD8+ mediated cel-
lular cytotoxicity. One long-lasting complete response (>18
months) and 3 extended survivals support further trials. No
adverse effects related to treatment were informed.
A vaccine against dog telomerase reverse transcriptase
(dTERT) transferred by adenoviral vector electroporation
was also proposed [42] as a valid target for immunotherapy of
malignant lymphoma when combined with standard chemo-
therapy regimen. dTERT-specific immune response was
induced in 13 out of 14 treated animals (93%) and remained
detectable and long-lastingwith the absence of autoimmunity
or other side effects. Most interestingly, the survival time of
vaccine/chemotreated dogs was significantly increased over
historic controls of chemotreated animals (>97.8 versus 37
weeks). Following this study, a double-arm clinical trial with
an extended number of B-cell lymphoma patients was con-
ducted [43], to measure the antigen-specific immune
response and to evaluate the potential toxic effects of immu-
notherapy during 3.5 years of follow-up. Without adverse
effects, the overall survival time of vaccine/chemotherapy-
treated dogs was significantly increased over the chemo-
therapy-only group (>76.1 versus 29.3 weeks) and dTERT
expression levels in tumor cells correlated with overall
survival among vaccinated patients.
Based on a RNAmediated gene therapy, a completely dif-
ferent way was proposed to treat non-Hodgkin’s lymphoma
[44]. In that case, when administered to dogs in remission
after induction chemotherapy, ex vivo autologous tumor
RNA electroporated CD40-activated B cells safely stimulated
immunity in vivo. This approach was safe and potentiated
the effects of salvage therapy, improving the rate of durable
second remissions as well as subsequent lymphoma-specific
survival following salvage therapy.
6. Other Canine Tumors
Electrochemogene therapy (ECGT) combining electropora-
tion with a feline interleukin-12 (fIL-12) carrying plasmid
and bleomycin was very effective [45]. It was able to control
two oral squamous cell carcinomas and one acanthomatous
ameloblastoma tumor that displayed long-lasting complete
responses (56, 27, and 9 months tumor-free, resp.).
An astrocytoma bearing patient was treated by a combi-
nation of surgery, intracavitary adenoviral human interferon-
𝛾 (IFN-𝛾) gene transfer, and vaccination with glioma cell
lysates mixed with CpG oligodeoxynucleotides [46]. Tran-
sient neurological symptoms were resolved and this dog
remained tumor-free over 450 days following surgery.
Intramuscular electrogene therapy (EGT) with plasmid
encoding human interleukin-12 (hIL-12) was assayed in dogs
with spontaneously occurring tumors, being a feasible and
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safe procedure. The systemic transgene expression of hIL-12
induced endogenous canine IFN-𝛾 release and tumor growth
control in 4 of 6 treated dogs (complete response for twomast
cell tumors and stable disease for one pulmonary histiocytic
sarcoma and one osteosarcoma) [47].
Malignant cutaneous canine mast cell tumors were
treated with EGT using DNA plasmid encoding hIL-12 [48].
This treatment produced a significant reduction of treated
tumors’ size, ranging from 13% to 83% (median 50%) of the
initial tumor volume (𝑛 = 8).There were histological changes
and a reduction in number of malignant mast cells, as well as
an inflammatory cell infiltration of treated tumors. No local
or systemic adverse side effects were detected.
7. Feline Fibrosarcoma
Fibrosarcoma is a deadly disease in cats and is significantly
more often located at classical vaccine injections sites. Due
to poor cure rates with surgery alone, the additional use of
adjuvant radiation therapy and/or chemotherapy has been
under investigation at multiple veterinary cancer centers for
the last few years [49].
Thepioneeringwork of veterinary cancer gene therapy [2]
also described the effects of the ex vivo genetically engineered
xenogeneic cell gene therapy approach on the highly invasive
feline fibrosarcoma that often presents postsurgical local
relapse. There, they evaluated the effects of repeated peritu-
moral local injections of human IL-2 secreting cells after sur-
gical removal of the tumor followed by 192Ir-brachytherapy.
This combined treatment resulted in a significantly longer
median survival of > 480 days compared to 240 days of
the surgery plus radiation controls (both groups: 𝑛 = 16).
Interestingly the combined treatment drastically reduced the
relapse rate after 480 days of treatment from 69% in the
control group to 31%.
In a different approach, the peritumoral injection of feline
IL-2 or human IL-2 genes carried by poxviral vectors was
assayed as adjunct treatment following surgery and 192Ir-
brachytherapy for feline fibrosarcoma [50]. The treatment
significantly diminished the rate of recurrence at day 365
from 11/18 (control) to 5/18 (feline IL-2) and 7/18 (human IL-
2).
A feasibility study combined fractionated radiotherapy,
hyperthermia, and heat-inducible intratumor adenoviral fIL-
12 gene therapy for feline soft tissue sarcoma determining the
dose-dependent systemic toxicity in phase I trial [51].
Two reports from the same research team used magneto-
fection for intratumoral gene delivery of feline fibrosarcoma.
The first one was phase I dose-escalation study to determine
a safe dose [52]. Twenty-five client-owned cats with clinical
diagnosis of fibrosarcoma—primary tumors as well as recur-
rences—entered the study. Four increasing doses of plas-
mids coding for feline cytokines fIL-2, fIFN-𝛾, or fGM-CSF
(from 15 to 450 𝜇g each) were assayed. Two preoperative
intratumoral injections of the magnetic DNA solution were
followed by magnetofection. With only 1 of 25 treated cats
showing adverse events at the highest dose, the treatment
was considered to be safe. Altogether 6 cats developed local
recurrences during a 1-year observation period. A second
phase I dose-escalation study was performed to determine
toxicity and feasibility of gene therapy with fGM-CSF coding
plasmid attached to magnetic nanoparticles (from 50 to
1250 𝜇g) in 20 cats with fibrosarcomas [53]. Two preoperative
intratumoral injections followed by magnetofection were
given. Without significant treatment related toxicity, 10 of 20
treated cats were recurrence-free on day 360.
8. Equine Melanoma
Melanomas are among the most common skin tumors in
horses, with prevalence rates reaching as high as 80% in adult
gray horses. Most melanocytic tumors are benign at initial
presentation; however, if left untreated, up to two-thirds can
progress to overt malignant behavior and there are limited
therapeutic options in metastatic disease [54].
Based on our experience with spontaneous canine
melanoma, we assayed the combination of local suicide gene
therapy with a cancer vaccine following surgical removal of
the superficial tumors in a singlemale gray horse patient with
metastatic melanoma [55]. The patient presented multiple
grouped superficial perianal and foreskin lesions that were
surgically removed. Some isolated subcutaneous masses in
the neck, back, and shoulders that were injected with the sui-
cide gene plus prodrug (HSV-tk gene carrying plasmid, gan-
ciclovir). Excised tumors were used to prepare a vaccine that
was subcutaneously injected in the flanks as scheduled for
canine treatment [29]. No undesirable side effects were
observed.After a six-month lasting treatment, the patient that
survived more than 2 years recovered its quality of life
including its full reproductive function, without local relapse
at the surgery areas.
As far as we know there are only three additional reports
on equine cancer gene therapy. In the first one [56]melanoma
metastases in gray horses were treated with a plasmid encod-
ing immunostimulatory hIL-12 (𝑛 = 7). A mean reduction in
tumor size to 41% was observed after one cycle, compared to
88% in the group treated with noncoding control vector and
107% in untreated animals. This transient volume reduction
could be repeated with subsequent hIL-12 plasmid transfer.
No side effects of the treatment were observed. In the second
trial, a randomized double-blind, placebo-controlled study
was conducted to investigate the antitumor effects of hIL-18-
or hIL-12-encoding plasmid DNAs, intratumorally injected
in gray horses with metastatic melanoma [57]. Significant
tumor regression could be shown in both cytokine gene
treated groups whereas placebo-treated control patients
showed tumor growth. In addition, 7 of 10 tumors fromhorses
treated with hIL-18 or hIL-12 showed peritumoral and/or
intratumoral inflammatory infiltrates after treatment com-
pared with 1 of the 6 in the control group. The treatment was
safe and well tolerated.
In a parallel study [58], 7 grey horses bearing melanoma
were intratumorally injected with 250𝜇g of naked plasmid
DNA coding for equine IL-12 (eIL-12). More than 99% of
the plasmid disappeared within 36 hours. The variable quick
increase of IFN-𝛾 expression after eIL-12 plasmid injection
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indicated biological activity. Intratumoral injection of plas-
mid DNA was a feasible method for inducing transgene
expression in vivo.
9. Conclusion
Most of the veterinary cancer gene therapy trials on patients
with spontaneous tumors could be classified as immuno-
gene therapy and were performed with nonviral vectors.
In general terms very slight or no adverse collateral effects
were found and most of the times treated animals displayed
a better course of the disease (longer survival, delayed or
suppressed local or systemic relapse, and recovery of the
quality of life) suggesting the utility of this sort of strategies
as standard adjuvant treatments. Besides, some of these
trials also demonstrated the utility of spontaneous tumors
in companion animals as a valid translational model for the
evaluation of novel DNA based therapies.
Two emerging approaches were supported by a large
number of treated patients: the xenogeneic vaccine [16] and
the suicide gene plus autologous/allogeneic vaccine [29, 30].
Both systems based the systemic disease control on the
immune system following the surgical removal of the tumor.
While the first approach using hTyr vaccine was specific for
melanoma [18], the second approach appeared to be more
versatile, because it was successfully translated to other kinds
of tumors such as soft tissue sarcoma [34] and osteosarcoma
[37].
As it is the case for human patients, usually survival
times for those veterinary patients that displayed objective
responses were significantly higher than for nonresponders.
In addition better results were obtained when treating the
early stages of the disease and, in the case of advanced disease
presenting bulky tumors, previous standard procedures such
as surgery, chemotherapy, and/or radiotherapy were neces-
sary to obtain the best outcome of the whole treatment.
It is worth to note that the efficacy displayed by plasmid-
based nonviral vectors used in 80% of the trials involving
large animals demonstrated their usefulness for present and
future gene therapy treatments. On the other hand, new
developments in oncolytic adenoviral vectors were recently
reported [59] and they could be eventually combined with
immunogene therapy approaches. Because of safety issues
and the costs of vector production, nonviral vectors are more
likely to be sooner approved and available for the treatment
of veterinary oncologic patients.
Although intravenous injections of cationic lipid: DNA
complexes had some immune mediated antitumor activity
against canine soft tissue sarcoma regardless the transgene
carried by the plasmid in the case of angiostatin “therapeutic”
or luciferase “reporter” gene [60], this fact should not be
taken as a negative result. In addition to the immune
enhancing effects of complexes carrying noncoding plasmid
in a vaccine proposed against hemangiosarcoma [61], the
expression of therapeutic genes displayed specific antitumor
activity as repeatedly evidenced in many papers listed in
Tables 1, 2, and 3. Further work has to be done to ascertain
the contribution of each component in vivo.
To avoid local recurrence, cancer control requires not
only converting the immune tumor environment from tol-
erant to competent, but also waking a systemic immune
response against the metastatic spread. Being cancers com-
plex diseases that involve multiple interactions among many
cell types beyond tumor and immune cells, the most effective
cancer therapies may consist of combinations of diverse
immunogene therapy strategies with other cytotoxic gene
therapies as well as rational combinationswith other standard
therapies such as surgery, radiotherapy, targeted molecular
therapies, and conventional chemotherapy. As displayed in
Tables 1 and 2,most of canine and feline immunogene therapy
trials were combined with the above-mentioned standard
therapies.
An increasing interest in cancer therapy trials in compan-
ion animals (especially dogs and cats) including those using
gene therapy techniques will serve as concept, safety, and
effectiveness proofs. Despite the complexity for developing
multicenter consortia capable of conducting clinical studies
in advance or in parallel with human clinical trials, this new
trend in the research of novel cancer therapies would indeed
benefit both companion animals and human patients [5, 62–
64].
Trials in companion animals are shorter in time and
at lower costs than in humans. Nowadays, there are con-
ditions for the development of translational research in
the oncology field [65, 66], intending to apply scientific
information to solve present problems in relatively brief
periods of time. Proper cancer models involving companion
animals spontaneously induce the investigators towork in the
duality between the veterinary perspective and the potential
application to human medicine. However, these are not
contradictory objectives, andmore trials in humans based on
the equivalent trials in pets will possibly come soon.
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